daa ’ s in the treatment of hcv: the beginning of the end or the end of the beginning for hcv?
DESCRIPTION
DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?. HCV-Related Cirrhosis Is Projected to Peak Over the Next 10 Years . Sustained Virologic Response Improves Overall Survival in Chronic HCV with Advanced Fibrosis. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/1.jpg)
DAA’s in the treatment of HCV: The Beginning of the end or the end of the
beginning for HCV?
![Page 2: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/2.jpg)
![Page 3: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/3.jpg)
![Page 4: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/4.jpg)
HCV-Related Cirrhosis Is Projected to Peak Over the Next 10 Years
![Page 5: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/5.jpg)
Sustained Virologic Response Improves Overall Survival in Chronic HCV with Advanced Fibrosis
![Page 6: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/6.jpg)
![Page 7: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/7.jpg)
DAAs as Components of New Treatment Paradigm for Hepatitis C
![Page 8: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/8.jpg)
![Page 9: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/9.jpg)
Eric the Sailor
![Page 10: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/10.jpg)
The story continues
![Page 11: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/11.jpg)
Interferon has a Dual Mechanism of Action: Viral Inhibition and Immune Modulation
![Page 12: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/12.jpg)
The addition of RBV Significantly Accelerates Viral Decay
![Page 13: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/13.jpg)
Pharmacokinetics of Once Daily Compared with Twice Daily Regimen of Ribavirin
![Page 14: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/14.jpg)
Eric’s HCV Treatment course
![Page 15: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/15.jpg)
Definitions of Response
![Page 16: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/16.jpg)
![Page 17: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/17.jpg)
![Page 18: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/18.jpg)
![Page 19: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/19.jpg)
![Page 20: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/20.jpg)
![Page 21: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/21.jpg)
DAAs - Key Characteristics
![Page 22: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/22.jpg)
Protease Inhibitor DAAs in Clinical Trials
![Page 23: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/23.jpg)
5 Non Nucleoside Polymerase Inhibitors
![Page 24: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/24.jpg)
4 Nucleoside Analogue Polymerase Inhibitors
![Page 25: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/25.jpg)
4 NS5A Inhibitors
![Page 26: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/26.jpg)
3 Other Classes
![Page 27: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/27.jpg)
Eric Update
![Page 28: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/28.jpg)
Eric comes ashore
![Page 29: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/29.jpg)
Rash Decisions
![Page 30: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/30.jpg)
Progress on study
![Page 31: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/31.jpg)
![Page 32: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/32.jpg)
Eric Week 24 to 48 and 72
![Page 33: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/33.jpg)
Newly Approved HCV Agents: Telaprevir and Boceprevir
![Page 34: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/34.jpg)
Treatment Naïve HCV G1
![Page 35: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/35.jpg)
Sprint 2 Boceprevir Naïve
![Page 36: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/36.jpg)
Sprint 2 SVR and Relapse Rates
![Page 37: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/37.jpg)
SPRINT-2 and RESPOND-2: HCV G1 Subtype as a Predictor of SVR in Patients with Poor IFN Response (BOC Arms Combined)
![Page 38: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/38.jpg)
Patients With Poor Interferon Response and Fail Treatment Are More Likely to Have RAVs
![Page 39: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/39.jpg)
![Page 40: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/40.jpg)
Changes in HCV RNA over Time During Previous Phase I Studies (101/103)
![Page 41: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/41.jpg)
C219: HCV RNA Values over Time (Week 8 Interim Analysis, TVR-exposed)
![Page 42: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/42.jpg)
MK 5172 Second Generation PI
![Page 43: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/43.jpg)
![Page 44: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/44.jpg)
Advance: SVR and Relapse Rates
![Page 45: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/45.jpg)
Previously Treated Patients HCV G1
![Page 46: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/46.jpg)
Respond-2
![Page 47: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/47.jpg)
Respond-2
![Page 48: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/48.jpg)
![Page 49: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/49.jpg)
REALIZE: Insulin resistance was not an independent determinant of SVR
![Page 50: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/50.jpg)
REALIZE: Impact of anemia/RBV dose reduction on SVR
![Page 51: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/51.jpg)
PILLAR Study:TMC 435SVR24 (ITT)
![Page 52: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/52.jpg)
Silen C 1 Virologic response BI 1335
![Page 53: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/53.jpg)
Atlas Efficacy: Achievement of HCV RNA <15 IU/mL
![Page 54: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/54.jpg)
![Page 55: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/55.jpg)
PSI-7977 ELECTRON: Study Design for HCV GT2/3
![Page 56: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/56.jpg)
PSI-7977 ELECTRON100% concordance of SVR12 with SVR24
![Page 57: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/57.jpg)
PSI-7977 ELECTRONWhat is the role of Ribavirin?
![Page 58: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/58.jpg)
BI 201335 and BI 207127, with and without ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Week 12
interim results of the SOUND-C2 study
![Page 59: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/59.jpg)
SVR-12
![Page 60: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/60.jpg)
Background
![Page 61: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/61.jpg)
BMS-790052 (NS5A inhibitor) + BMS-650032 (PI) ± PR in null responders: phase IIa study
![Page 62: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/62.jpg)
Virologic Response before and after treatment
![Page 63: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/63.jpg)
![Page 64: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/64.jpg)
Dual therapy with BMS 790052 + BMS 650032 in HCV genotype 1B null responsders
![Page 65: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/65.jpg)
![Page 66: DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?](https://reader036.vdocuments.net/reader036/viewer/2022062810/56815e28550346895dcc8295/html5/thumbnails/66.jpg)
The Holy Grail